

Amended.
application is a continuation-in-part of application Serial No. 08/079,601, filed June 22, 1993, now U.S. Patent No. 5,523,089, which is a continuation of U.S. application Serial No. 07/924,798, filed August 6, 1992, now abandoned, which is a continuation of U.S. application Serial No. 07/422,881, filed October 18, 1989, now abandoned, claiming priority from Danish application 5902/88, filed October 24, 1988. *AMM*

Page 1, line 13 (eighth line under "Related Applications"), please change "_____" to --08/588,621--.

Page 3, line 23, please change "PRC/US92/08697" to --PCT/US92/08697--.

IN THE CLAIMS

Please amend the claims as follows:

aa
1. (Amended) A method for inducing an immunological response in a mammalian host susceptible to Lyme disease or *Borrelia burgdorferi* infection comprising mucosally administering [isolated] a composition comprising substantially pure [Borrelia burgdorferi] outer surface protein A (OspA) [in admixture with] and a carrier or diluent.

2. (Amended) The method of claim 1 wherein the OspA is [purified recombinant,] lipidated OspA [substantially free of other bacterial proteins, and substantially free of LPS].

aa 3 amended.
6. (Amended) The method of claim 3 wherein the composition comprising substantially pure OspA [in admixture

with] and a carrier or diluent is free of any immunogenicity-enhancing adjuvant.

7. (Amended) The method of claim 1 wherein the OspA is recombinant OspA [A method for inducing an immunological response in a mammalian host susceptible to Lyme disease or *Borrelia burgdorferi* infection comprising mucosally administering a composition consisting essentially of isolated *Borrelia burgdorferi* OspA and a carrier or diluent].

8. (Amended) The method of claim 7 wherein the OspA is [purified recombinant,] lipidated [OspA substantially free of other bacterial proteins, and substantially free of LPS].

12. The [composition] method of claim 1[1] [which] wherein the composition comprising substantially pure OspA and a carrier or diluent is a solution, suspension, emulsion, syrup, elixir, capsule, tablet, hard-candy-like preparation, or a solid food item.

Please cancel claim 11, without prejudice, admission, or any intention of creating any estoppel as to equivalents, or any surrender of subject matter.

REMARKS

Reconsideration and withdrawal of the objections to and rejections of the application are respectfully requested in view of the amendments, remarks and attachments herewith.

The Office Action at page 1 cited certain typographical errors and noted that the drawings are informal. Typographical